Medication Identification: Is Asiminib the same as Asiminib?

Asciminib (Asciminib), also known as Scemblix, is an experimental drug developed by Novartis. Aceminib is a new allosteric inhibitor mainly used to treat chronic myelogenous leukemia (CML). It is a specific allosteric inhibitor targeting the myristoyl pocket (STAMP) of BCR-ABL1 protein. By binding to the myristoyl pocket of ABL1, aceminib inhibits the activity of BCR-ABL1, providing new treatment options for patients with TKI treatment resistance and/or intolerance and improving patient prognosis.

In patients who had already received at least two tyrosine kinase inhibitors, aceminib was more effective than another tyrosine kinase inhibitor in reducing the number of cells with theBCR::ABL1 gene. In terms of safety, the side effects of aceminib are similar to those of this class of drugs and are considered manageable. Thereforemany countries decided that the benefits of Asiminib outweighed its risks and it could be marketed for use, currently sold overseas asScemblix.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminil sold overseas is very expensive, and the price of 20mg*60 oral tablets is about more than 20,000 US dollars (the price may fluctuate due to the exchange rate). There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.